Overall survival describes the length of time from when your disease is first diagnosed or treatment has been started, until death. In clinical studies, overall survival is used to show how well certain treatments work.
In clinical studies of people with multiple myeloma who took Kyprolis, the overall survival was as follows:
half of the people taking Kyprolis with dexamethasone lived at least 47.6 months
half of the people taking Kyprolis with both dexamethasone and lenalidomide lived at least 48.3 months
If you have questions about the survival length with Kyprolis treatment, talk with your doctor.